Bioline Rx Ltd ADR (NASDAQ:BLRX) does about 793.79K shares in volume on a normal day but saw 1238483 shares change hands in the recent trading day. The company now has a market cap of 21.25M USD. Its current market price is $0.25, marking a decrease of -1.69% compared to the previous close of $0.25. The 52 week high reached by this stock is $1.89 whilst the lowest price level in 52 weeks is $0.25.
Bioline Rx Ltd ADR (BLRX) has a 20-day trading average at $0.3666 and the current price is -86.79% off the 52-week high compared with -0.12% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.4247 and its 200-day simple moving average is $0.6839. If we look at the stock’s price movements over the week, volatility stands at 11.65%, which decreases to 11.06% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 29.13 to suggest the stock is oversold.
The consensus objective for the share price is $4.57, suggesting that the stock has a potential upside of 94.53% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 18, 2017 when Maxim Group upgraded the stock to “Buy” and issued a price target of between $1 and $3. Maxim Group downgraded its price target at $4-$1.
The current price level is -31.89%, -41.20%, and -63.49% away from its SMA20, SMA50, and SMA200 respectively, with the BLRX price moving above the 50-day SMA on current market day. Bioline Rx Ltd ADR (BLRX) stock is down -15.93% over the week and -44.88% over the past month. Its price is -84.10% year-to-date and -84.87% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0.0 and -0.08 for whole year. Expected sales for next quarter are $792k, which analysts say will come at $24.91M for the current fiscal year and next year at $4.29M. In addition, estimates put the company’s current quarterly revenue at an average of $7.72M.
To reach the target analysts have set, the stock logically needs to grow 94.53 percent from here.
The company has a return on investment of -71.70% and return on equity of -184.09%. The beta has a value of 1.41. Price to book ratio is 2.35 and price to sales ratio is 0.97.
